Eledon advances Tegoprubart with new transplant trials and US regulatory filing

Eledon Pharmaceuticals has filed a US regulatory application for a company-led study of tegoprubart in type 1 diabetes patients undergoing islet cell transplants, as it pushes forward multiple transplant programmes and a broad kidney trial scheduled for late 2026. Eledon…













